FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096564238> ?p ?o ?g. }

• W2096564238 endingPage "11454" @default.
• W2096564238 startingPage "11447" @default.
• W2096564238 abstract "Abstract Allogeneic cell therapy as a means to break immunotolerance to solid tumors is increasingly used for cancer treatment. To investigate cellular alloimmune responses in a human tumor model, primary cultures were established from renal cell carcinoma (RCC) tissues of 56 patients. In three patients with stable RCC line and human leukocyte antigen (HLA)-identical sibling donor available, allogeneic and autologous RCC reactivities were compared using mixed lymphocyte/tumor cell cultures (MLTC). Responding lymphocytes were exclusively CD8+ T cells, whereas CD4+ T cells or natural killer cells were never observed. Sibling MLTC populations showed higher proliferative and cytolytic antitumor responses compared with their autologous counterparts. The allo-MLTC responders originated from the CD8+ CD62L(high)+ peripheral blood subpopulation containing naive precursor and central memory T cells. Limiting dilution cloning failed to establish CTL clones from autologous MLTCs or tumor-infiltrating lymphocytes. In contrast, a broad panel of RCC-reactive CTL clones was expanded from each allogeneic MLTC. These sibling CTL clones either recognized exclusively the original RCC tumor line or cross-reacted with nonmalignant kidney cells of patient origin. A minority of CTL clones also recognized patient-derived hematopoietic cells or other allogeneic tumor targets. The MHC-restricting alleles for RCC-reactive sibling CTL clones included HLA-A2, HLA-A3, HLA-A11, HLA-A24, and HLA-B7. In one sibling donor-RCC pair, strongly proliferative CD3+CD16+CD57+ CTL clones with non-HLA-restricted antitumor reactivity were established. Our results show superior tumor-reactive CD8 responses of matched allogeneic compared with autologous T cells. These data encourage the generation of antitumor T-cell products from HLA-identical siblings and their potential use in adoptive immunotherapy of metastatic RCC patients. (Cancer Res 2006; 66(23): 11447-54)" @default.
• W2096564238 created "2016-06-24" @default.
• W2096564238 creator A5019149690 @default.
• W2096564238 creator A5023962756 @default.
• W2096564238 creator A5036175709 @default.
• W2096564238 creator A5038905430 @default.
• W2096564238 creator A5040589443 @default.
• W2096564238 creator A5040663053 @default.
• W2096564238 creator A5050569543 @default.
• W2096564238 creator A5059069604 @default.
• W2096564238 creator A5066232501 @default.
• W2096564238 creator A5070308279 @default.
• W2096564238 creator A5073672091 @default.
• W2096564238 creator A5073827885 @default.
• W2096564238 creator A5074754127 @default.
• W2096564238 creator A5087138356 @default.
• W2096564238 date "2006-12-01" @default.
• W2096564238 modified "2023-10-15" @default.
• W2096564238 title "Superior Antitumor<i>In vitro</i>Responses of Allogeneic Matched Sibling Compared with Autologous Patient CD8+ T Cells" @default.
• W2096564238 cites W1274344746 @default.
• W2096564238 cites W1482170713 @default.
• W2096564238 cites W1483726034 @default.
• W2096564238 cites W1627619586 @default.
• W2096564238 cites W1667816862 @default.
• W2096564238 cites W1885055897 @default.
• W2096564238 cites W1887940719 @default.
• W2096564238 cites W1969900447 @default.
• W2096564238 cites W1975568557 @default.
• W2096564238 cites W1987288591 @default.
• W2096564238 cites W1995570137 @default.
• W2096564238 cites W2000289316 @default.
• W2096564238 cites W2003192353 @default.
• W2096564238 cites W2024107368 @default.
• W2096564238 cites W2024402262 @default.
• W2096564238 cites W2030230012 @default.
• W2096564238 cites W2032367681 @default.
• W2096564238 cites W2041027155 @default.
• W2096564238 cites W2060136712 @default.
• W2096564238 cites W2070854387 @default.
• W2096564238 cites W2073310925 @default.
• W2096564238 cites W2074345036 @default.
• W2096564238 cites W2091038501 @default.
• W2096564238 cites W2093176232 @default.
• W2096564238 cites W2097633205 @default.
• W2096564238 cites W2103694715 @default.
• W2096564238 cites W2104013211 @default.
• W2096564238 cites W2109837346 @default.
• W2096564238 cites W2113847305 @default.
• W2096564238 cites W2119174775 @default.
• W2096564238 cites W2119627739 @default.
• W2096564238 cites W2130374917 @default.
• W2096564238 cites W2132925083 @default.
• W2096564238 cites W2138163780 @default.
• W2096564238 cites W2148284955 @default.
• W2096564238 cites W2148523692 @default.
• W2096564238 cites W2150678612 @default.
• W2096564238 cites W2159877190 @default.
• W2096564238 cites W2167523219 @default.
• W2096564238 cites W2327749578 @default.
• W2096564238 cites W2334694951 @default.
• W2096564238 cites W4234763688 @default.
• W2096564238 doi "https://doi.org/10.1158/0008-5472.can-06-0998" @default.
• W2096564238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17145892" @default.
• W2096564238 hasPublicationYear "2006" @default.
• W2096564238 type Work @default.
• W2096564238 sameAs 2096564238 @default.
• W2096564238 citedByCount "21" @default.
• W2096564238 countsByYear W20965642382013 @default.
• W2096564238 countsByYear W20965642382014 @default.
• W2096564238 countsByYear W20965642382015 @default.
• W2096564238 countsByYear W20965642382016 @default.
• W2096564238 crossrefType "journal-article" @default.
• W2096564238 hasAuthorship W2096564238A5019149690 @default.
• W2096564238 hasAuthorship W2096564238A5023962756 @default.
• W2096564238 hasAuthorship W2096564238A5036175709 @default.
• W2096564238 hasAuthorship W2096564238A5038905430 @default.
• W2096564238 hasAuthorship W2096564238A5040589443 @default.
• W2096564238 hasAuthorship W2096564238A5040663053 @default.
• W2096564238 hasAuthorship W2096564238A5050569543 @default.
• W2096564238 hasAuthorship W2096564238A5059069604 @default.
• W2096564238 hasAuthorship W2096564238A5066232501 @default.
• W2096564238 hasAuthorship W2096564238A5070308279 @default.
• W2096564238 hasAuthorship W2096564238A5073672091 @default.
• W2096564238 hasAuthorship W2096564238A5073827885 @default.
• W2096564238 hasAuthorship W2096564238A5074754127 @default.
• W2096564238 hasAuthorship W2096564238A5087138356 @default.
• W2096564238 hasBestOaLocation W20965642382 @default.
• W2096564238 hasConcept C147483822 @default.
• W2096564238 hasConcept C147969180 @default.
• W2096564238 hasConcept C154317977 @default.
• W2096564238 hasConcept C167672396 @default.
• W2096564238 hasConcept C188280979 @default.
• W2096564238 hasConcept C202751555 @default.
• W2096564238 hasConcept C203014093 @default.
• W2096564238 hasConcept C2777701055 @default.
• W2096564238 hasConcept C54355233 @default.
• W2096564238 hasConcept C71924100 @default.
• W2096564238 hasConcept C86803240 @default.

• next